Supernus Pharmaceuticals

Supernus Pharmaceuticals is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system disorders. The Company launched Oxtellar XR and Trokendi XR, two novel neurology products for the treatment of epilepsy.  Supernus Pharmaceuticals is also developing several product candidates in psychiatry to address unmet medical needs and opportunities in attention-deficit hyperactivity disorder and its coexisting disorders, and depression.

Company Growth (employees)
Type
Public
HQ
Rockville, US
Founded
2005
Size (employees)
363 (est)+6%
Supernus Pharmaceuticals was founded in 2005 and is headquartered in Rockville, US

Key People at Supernus Pharmaceuticals

Jack Khattar

Jack Khattar

President and CEO

Supernus Pharmaceuticals Office Locations

Supernus Pharmaceuticals has an office in Rockville
Rockville, US (HQ)
1550 E Gude Dr

Supernus Pharmaceuticals Data and Metrics

Supernus Pharmaceuticals Financial Metrics

Supernus Pharmaceuticals's revenue was reported to be $57.6 m in Q1, 2017
USD

Revenue (Q1, 2017)

57.6 m

Gross profit (Q1, 2017)

54.6 m

Gross profit margin (Q1, 2017), %

95%

Net income (Q1, 2017)

10.3 m

EBIT (Q1, 2017)

16.8 m

Market capitalization (22-Aug-2017)

2.5 b

Cash (31-Mar-2017)

59.6 m
Supernus Pharmaceuticals's current market capitalization is $2.5 b.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

12 m122 m144.4 m215 m

Revenue growth, %

915%18%49%

Cost of goods sold

1.1 m5.8 m8.4 m12 m

Gross profit

10.9 m116.3 m136 m203 m

Gross profit Margin, %

91%95%94%94%

EBIT

(61.9 m)24.2 m17.7 m54.2 m

EBIT margin, %

(515%)20%12%25%

Interest income

299 k348 k643 k1.5 m

Net Income

(92.3 m)19.9 m14 m91.2 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Revenue

29.7 m52.5 m28.1 m35.1 m38.6 m43.1 m50.4 m56.8 m57.6 m

Cost of goods sold

1.7 m1.3 m1.6 m1.8 m2.2 m2 m2.8 m3.4 m2.9 m

Gross profit

28 m51.2 m26.5 m33.3 m36.3 m41 m47.7 m53.4 m54.6 m

Gross profit Margin, %

94%97%94%95%94%95%95%94%95%

R&D expense

4.7 m4.7 m3.7 m6.9 m9.1 m10.6 m11.1 m7.9 m9.6 m

General and administrative expense

19.6 m17.3 m19.4 m23.3 m22.9 m25.2 m26.1 m25.7 m28.2 m

Operating expense total

24.3 m22 m23.1 m30.2 m32 m35.7 m37.2 m33.5 m37.8 m

EBIT

3.8 m29.2 m3.4 m3.1 m4.3 m5.3 m10.4 m19.8 m16.8 m

EBIT margin, %

13%56%12%9%11%12%21%35%29%

Interest expense

1.3 m1.3 m381 k331 k292 k179 k196 k202 k90 k

Interest income

85 k78 k113 k137 k169 k331 k363 k379 k531 k

Pre tax profit

4.3 m5.2 m10.7 m19.1 m16.2 m

Income tax expense

62 k662 k58 k198 k714 k(42.7 m)5.9 m

Net Income

(12.3 m)15.5 m917 k2.9 m7.1 m5 m15 m76.9 m10.3 m
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

33 m36.4 m34.2 m66.4 m

Accounts Receivable

5.1 m17.3 m25.9 m41.5 m

Inventories

7.2 m3.8 m5.3 m16.8 m

Current Assets

97.2 m108.9 m106 m151.4 m

PP&E

2.6 m2.4 m3.9 m4.3 m

Total Assets

111 m137.5 m188.7 m309.6 m

Accounts Payable

18.3 m1.9 m4.3 m8.1 m

Current Liabilities

26.4 m27.5 m56.1 m80.7 m

Total Liabilities

117.8 m

Additional Paid-in Capital

212 m230.1 m264 m276.1 m

Retained Earnings

(178.5 m)(158.7 m)(144.6 m)(84.3 m)

Total Equity

33.5 m71.4 m118.9 m191.8 m

Financial Leverage

3.3 x1.9 x1.6 x1.6 x
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

12 m37.8 m25.8 m33.1 m26.3 m19.8 m36.2 m54.3 m59.6 m

Accounts Receivable

10.9 m15.3 m19.3 m17.9 m23.6 m30.7 m34.3 m36.2 m38.9 m

Inventories

10.1 m11.1 m13.7 m13.6 m14.7 m13 m16.4 m17.5 m19.2 m

Current Assets

72 m103 m101.5 m105.7 m102.6 m94 m114.1 m138.2 m149.8 m

PP&E

2.6 m2.5 m2.5 m2.9 m3.2 m3.9 m4.2 m4.3 m4.3 m

Total Assets

94.2 m126.3 m139.6 m154.2 m166.8 m194.5 m218.6 m285.1 m322.3 m

Accounts Payable

19 m22 m859 k4.5 m2.8 m2.6 m2.2 m2.7 m5.1 m

Current Liabilities

19.2 m22.1 m26.9 m36.4 m43.1 m54.1 m65.6 m71.6 m82 m

Additional Paid-in Capital

224.2 m229.1 m252.3 m258.2 m261 m267.6 m270.1 m271.8 m279.8 m

Retained Earnings

(190.9 m)(163 m)(157.7 m)(155.7 m)(151.5 m)(139.7 m)(129.6 m)(98.6 m)(73.8 m)

Total Equity

33.4 m66.1 m94.6 m102.4 m109.4 m128.1 m141 m173.4 m206.1 m

Financial Leverage

2.8 x1.9 x1.5 x1.5 x1.5 x1.5 x1.6 x1.6 x1.6 x
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(92.3 m)19.9 m14 m91.2 m

Depreciation and Amortization

742 k928 k921 k2.4 m

Accounts Receivable

(5 m)(12 m)(8.6 m)(15.6 m)

Inventories

(6 m)(6.3 m)854 k(4.2 m)

Accounts Payable

8.5 m(1.3 m)2.1 m3.5 m

Cash From Operating Activities

(57.9 m)7.7 m32.1 m66.8 m

Purchases of PP&E

(2.1 m)(1.6 m)

Cash From Investing Activities

(12.1 m)(4.9 m)(36.2 m)(36 m)

Cash From Financing Activities

62.7 m570 k1.9 m2.1 m

Interest Paid

2.9 m825 k493 k
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(12.3 m)15.5 m917 k2.9 m7.1 m5 m15 m76.9 m10.3 m

Depreciation and Amortization

460 k701 k214 k431 k651 k429 k1.1 m1.7 m741 k

Accounts Receivable

(5.8 m)(10.2 m)(2 m)(630 k)(6.3 m)(4.7 m)(8.4 m)(10.3 m)2.6 m

Inventories

(2.9 m)(4 m)(261 k)(151 k)(1.3 m)(457 k)(3.8 m)(4.9 m)(2.4 m)

Accounts Payable

730 k3.7 m(1 m)2.7 m949 k(1.7 m)(2.1 m)(1.6 m)(3.1 m)

Cash From Operating Activities

(26 m)739 k503 k15.2 m12.2 m(3.1 m)13.6 m41.9 m13.4 m

Purchases of PP&E

(1.2 m)(279 k)(903 k)(1.3 m)(300 k)

Cash From Investing Activities

4.8 m3.8 m(11.2 m)(19.5 m)(23.4 m)(11.3 m)(12.6 m)(22.3 m)(20.8 m)

Cash From Financing Activities

250 k264 k147 k1 m1.1 m124 k995 k1.3 m604 k

Interest Paid

1.5 m1.5 m504 k504 k247 k247 k
USDY, 2017

Revenue/Employee

162.9 k

Financial Leverage

1.6 x

Supernus Pharmaceuticals Market Value History

Traffic Overview of Supernus Pharmaceuticals

Supernus Pharmaceuticals Company Life and Culture

You may also be interested in